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Abstract
Pioneering work in the 1990’s first linked a novel microaerobic bacterium, Helicobacter
hepaticus, with active chronic hepatitis and IBD in several murine models. Targeted H. hepaticus
infection experiments subsequently demonstrated its ability to induce colitis, colorectal cancer,
and extra-intestinal diseases in a number of mouse strains with defects in immune function and/or
regulation. Helicobacter hepaticus is now widely utilized as a model system to dissect how
intestinal microbiota interact with the host to produce both inflammatory and tolerogenic
responses. This model has been used to make important advances in understanding factors that
regulate both acquired and innate immune response within the intestine. Further, it has been an
effective tool to help define the function of regulatory T cells, including their ability to directly
inhibit the innate inflammatory response to gut microbiota. The complete genomic sequence of H.
hepaticus has advanced the identification of several virulence factors and aided in the elucidation
of H. hepaticus pathogenesis. Delineating targets of H. hepaticus virulence factors could facilitate
novel approaches to treating microbially induced lower bowel inflammatory diseases.
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Initial isolation and characterization of H. hepaticus and H. bilis
Since the isolation and characterization of Helicobacter pylori, the etiologic agent of peptic
ulcer disease in 1983, a number of other Helicobacter species have been isolated, many of
which can produce serious non-gastric disease in their respective hosts. Helicobacter species
that colonize the lower bowel and biliary tract of mice have been associated with the
development of colitis resembling human inflammatory bowel disease (IBD) in susceptible
hosts. Further, H. hepaticus infection has been demonstrated to exacerbate the development
of cancer at both intestinal and extraintestinal sites. The most well studied member of this
group of enterohepatic Helicobacter species (EHS) is Helicobacter hepaticus. In this review
we will focus on the initial identification of H. hepaticus, the basis for H. hepaticus-induced
lower bowel inflammation, and the characterization of bacterial virulence factors.
In the early 1990’s, an active chronic hepatitis was detected in several inbred strains of mice
including A/JCr, originating from a barrier-maintained facility. A distinctive morphological
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pattern of liver damage was noted which had not been previously identified in mice. Using a
special silver stain, a spiral-like organism was observed in the liver. Infected A/JCr mice
were then shipped to our laboratory for characterization and diagnostic evaluation. A
microaerobic bacterium was consistently isolated from the liver and colon of these mice
between 3 and 18 months of age. By biochemical and molecular methodologies these
bacteria were confirmed to represent a new Helicobacter sp. which we named H.
hepaticus 1-3. Shortly after the isolation of H. hepaticus, we isolated a fusiform bacterium
from the liver, bile, and lower intestine of aged, inbred mice. On the basis of 16S rRNA
gene sequence analysis, the organism was classified as a novel Helicobacter sp., H. bilis.
Currently there are 9 formally named EHS isolated from mice as well as several other novel
Helicobacter spp. awaiting formal naming. Most recently, H. pullorum, a human pathogen,
has been isolated from commercial, barrier maintained mice 4. Surveys conducted in 1995
and 2007 indicated that H. hepaticus as well as other EHS have a worldwide distribution in
academic and commercial mice 5, 6. Contrary to the earlier survey, no Helicobacter spp.,
however, were found in mice in 2007 from advertised Helicobacter-free production areas
from two U.S. vendors. These results demonstrated that infection with EHS is wide spread
in most if not all mouse colonies used for experimental investigations.
Spontaneous IBD in immunodeficient and genetically engineered mice:
Association with Helicobacter spp
Prior to the isolation of EHS, it had been speculated that microflora might play an important
role in the etiology of spontaneous colitis that developed in a number of immunodeficient
laboratory mouse strains including IL-10-deficient, scid, and RAG. Berg et al. also
demonstrated that inbred mice on different strain backgrounds with undefined intestinal
flora influenced the degree of colitis and lower bowel adenocarcinoma noted in mice;
C57BL IL10−/− were less prone to develop colitis and carcinoma, Balbc IL10−/− were
intermediate in susceptibility and 129 IL10−/− mice developed the most severe disease 7.
Once identified, we found that while H. hepaticus infection could be demonstrated in a
number of immunologically normal mice without colitis, it was strongly associated with
chronic proliferative typhlitis, colitis, and rectal prolapse in several immunodeficient mouse
strains housed at NCI and MIT 8, 9. The specific pathogen-free health status of these
colonies was verified to include lack of serum antibodies to murine viruses and negative
cultures for respiratory pathogens, Salmonella sp., and Citrobacter rodentium. These
findings suggested infection with H. hepaticus was strongly associated with the
development of colitis in a number of laboratory mouse strains, and raised the question of
whether H. hepaticus might be an etiologic agent of murine colitis.
Establishing the Link Between Helicobacter spp. and IBD
To establish the link between H. hepaticus and the development of colitis, we demonstrated
that H. hepaticus inoculated into Helicobacter spp. free defined flora C.B. 17 scid mice
reconstituted with CD45RBhigh T cells resulted in severe IBD, similar to that noted with
human disease 10. The expression of typhlitis and colitis was statistically less severe in
defined flora scid mice that had been reconstituted with T cells but not infected with H.
hepaticus when compared to reconstituted scid mice infected with H. hepaticus 10,
demonstrating that infection with this single species could significantly exacerbate colitis in
a murine disease model 11, 12. Similar results were obtained following targeted infection of
C57BL IL-10-deficient mice with H. hepaticus 13, 14. Targeted infection experiments have
now demonstrated that H. hepaticus is able to induce colitis and in some cases lower bowel
carcinoma in a number of mouse strains with defects in immune function and/or regulation
(Table 1). Interestingly, the same strain susceptibility noted by Berg et al in IL10−/− mice
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was also documented in Rag−/− mice developing colitis associated lower bowel carcinoma
when experimentally infected with H. hepaticus 7, 15.
Basis of the GI inflammatory response to H. hepaticus
The experiments described indicate that H. hepaticus infection can induce colitis in certain
susceptible mouse strains, but the nature of the inflammatory response and why certain
strains were susceptible required further investigation. Seminal experiments from the early
1990’s demonstrated that mice lacking IL-10 developed spontaneous colitis, which was
significantly less severe when mice were housed in SPF conditions, suggesting enhanced
susceptibility to microbiota induced inflammation 16. In contrast to H. hepaticus
monoassociated C57BL IL10−/− mice which did not develop colitis, Kullberg and co-
workers directly demonstrated that targeted infection of SPF housed C57BL IL-10 mice
with H. hepaticus significantly exacerbated the development of colitis 13, 17. The
inflammatory response in the H. hepaticus-infected C57BL IL-10-deficient mice was
characterized by a Th1-like cytokine profile 13, 18. More recently these results have been
replicated by demonstrating that wild-type (WT) C57BL mice treated with an antibody
directed at the IL10 receptor (anti-IL-10R), but not those treated with a control antibody,
develop colitis following infection with H. hepaticus 19. Colitis in anti-IL-10R treated mice
is characterized by increased expression of mRNA coding for IFN-γ and IL-17 within the
colon. Mesenteric lymph node cells (MLNs) derived from H. hepaticus-infected mice
treated with anti-IL-10R secreted higher levels of IL-17 and IFN-γ compared to control
mesenteric lymph node cells following exposure to soluble helicobacter antigen 19. Mice-
deficient in IL-12p40 but not those deficient in IL-12p35 were resistant to H. hepaticus-
induced colitis following anti-IL-10R treatment, which was associated with decreased
expression of IFN-γ and IL-17, suggesting that IL-23 rather than IL-12p70 was necessary
for the generation of both Th1 and Th17 responses observed following H. hepaticus
infection. These experiments indicated that H. hepaticus can induce antigen-specific Th1
and Th17 responses in mice with impaired IL-10 signaling.
While H. hepaticus infection of mice with impaired IL-10 signaling induces CD4-mediated
Th1 and Th17 responses, the exact role of both IFN-γ and IL-17 in H. hepaticus-mediated
colitis has been more difficult to discern. Initial experiments with an IFN-γ depleting
antibody suggested that IFN-γ was necessary for H. hepaticus to induce colitis in IL-10-
deficient mice 13. However, the severity of H. hepaticus-induced colitis in mice doubly-
deficient for IL-10 and IFN-γ was very similar to that in mice lacking IL-10 alone 18.
Further, whereas H. hepaticus-induced inflammation within the colon of IFN-γ-deficient
mice treated with anti-IL-10R was decreased compared to similarly treated WT mice, there
was no difference in the level of inflammation in the cecum between genotypes 19. Although
to our knowledge, the role of IL-17 in regulating H. hepaticus-induced inflammation in mice
with impaired IL-10 signaling has not been directly tested, there are conflicting results from
experiments testing the role of IL-17 in the development of colitis that develops follow the
adoptive transfer of CD4+CD45RBhigh cells into lymphocyte-deficient hosts 20, 21. Further,
as it has been suggested that other Th17 cell-derived cytokines such as Il-17F 20 and
IL-22 22, 23 can modulate disease severity in T cell-dependent models of colitis, the role of
these cytokines in H. hepaticus-dependent colitis requires additional study.
Although the exact role of T helper subsets in the development of H. hepaticus-induced
colitis in susceptible hosts remains to be determined, increasing evidence has focused
attention on the innate inflammatory response to H. hepaticus. Early studies demonstrated
that H. hepaticus could induce colitis in certain strains of lymphocyte-deficient mice
including scid and 129SvEv/Rag−/− 10, 24-27, and progressed to colonic carcinoma with
neoplastic peritoneal invasion in some murine models 24, 28. H. hepaticus-induced innate
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colitis appeared to be dependent upon IL-23, as antibody depletion of both IL-12 p40 and
IL-12 p19 (the components of IL-23) inhibited H. hepaticus-induced colitis in 129SvEv/
Rag-/- mice 29. Antibody depletion assays have also demonstrated an important role for TNF
in H. hepaticus-induced innate colitis 25.
Surprisingly, even in the innate colitis model, H. hepaticus infection induced robust levels of
the T helper associated cytokines IL-17 and IFN-γ within the colon of 129SvEv/Rag−/−
mice 29, and treatment of H. hepaticus-infected 129SvEv/Rag−/− mice with either IL-17 or
IFN-γ depleting antibody ameliorated colitis 30. This suggested that cells of the innate
immune system expresses IL-17 and IFN within the colon following H. hepaticus infection.
Indeed, in 129SvEv/Rag−/− mice infected with H. hepaticus, there was a marked increase in
the percentage of colonic lamina propria (LP) cells that stain positively for IL-17 alone or
both IL-17 and IFN-γ following overnight stimulation with IL-23 30. These IL-17± cells
lacked lineage markers (CD11b, GR1, B220), but expressed high levels of Thy1 30, and thus
bear similarities to a previous described rare population of lamina propria cells termed
Lymphoid Tissue inducer-like (LTi-like) cells 31, 32. Some LTi-like cells express CD4 on
their cell surface 31, while these newly described IL-17+ innate lymphoid cells do not 30.
However they share a number of other cell surface markers including IL-7Rα 30, 31.
Interestingly, there was a marked increase in the frequency of Thy1high innate lymphoid
cells within the colonic lamina propia of 129SvEv/Rag−/− following H. hepaticus infection,
and when isolated by sorting, these cells produced IFN-γ, IL-17, and IL-22 after overnight
culture, which was enhanced by treatment with IL-23 30.
It has previously been shown that the development of LTi and LTi-like cells, as well as
classic Th17 cells require the transcription factor, RORγt 31-33. Interestingly, H. hepaticus-
induced innate−Thy1high+ LP cells expressed higher levels of RORγt than remaining Thy1−
LP cells 30, and both C57BL/6Rag−/− mice treated with anti-Thy1 antibody, or C57BL/
6Rag−/− mice that lacked the gene for RORγt, were resistant to anti-CD40-induced innate
colitis 30. These data strongly suggest that Thy1+ RORγt-expressing innate lymphoid cell
plays a critical role in driving intestinal inflammation. Further, if these innate lymphoid cells
require the IL-7 receptor for their survival and/or expansion in similar fashion to LTi
cells 34, this could explain the earlier observation that H. hepaticus is unable to induce
colitis in 129SvEv/Rag−/− mice that also lack IL-7 27.
These studies argue that innate immune mechanisms play a critical role in the ability of H.
hepaticus to induce colitis in susceptible hosts. However, it is important to recognize that H.
hepaticus infection does not induce colitis in most WT mouse strains despite persistent
infection, suggesting that a lymphocyte-mediated mechanism inhibits H. hepaticus-induced
innate inflammation. Consistent with this, several groups have shown that the adoptive
transfer of CD4+CD25+ T regulatory-cells into 129SvEv/Rag−/− mice can inhibit the
development of colitis following H. hepaticus infection 25, 28. Inhibition depends upon the
ability of transferred cells to express IL-10, as IL-10-deficient CD4+CD25+ T cells are
unable to inhibit H. hepaticus-induced innate inflammation, and in fact appear to exacerbate
disease 24, 25. Remarkably, transfer of CD4+CD25+ T regulatory cells into H. hepaticus-
infected 129SvEv/Rag−/− mice with colitis leads to rapid resolution of disease 24, 35. Several
studies revealed that potency of CD4+CD25+ to protect against or treat IBD can be enhanced
by H. hepaticus infection of donor mice 36, 37. Thus CD4+CD25+ T regulatory cells can both
inhibit and treat H. hepaticus-induced innate inflammation in the lower bowel, based on an
IL-10-dependent mechanism. Interestingly, CD25+ cells are not the only CD4+ subtype with
regulatory activity, as it has been demonstrated that CD4+CD45RBlowCD25− cells harvested
from H. hepaticus infected C57BL/10 mice are potent inhibitors of colitis induced by
adoptive transfer of IL-10-deficient CD4+ T cells into H. hepaticus-infected C57BL/
10Rag−/− mice 36.
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Experiments described above indicating that the recognition of H. hepaticus by the innate
immune system plays a key role in regulating the ensuing inflammatory response in the
lower bowel, suggest that understanding the innate inflammatory signaling pathways and
receptors utilized by H. hepaticus could lead to important insights into the basis of
microbiota-driven colonic inflammation. H. hepaticus challenge of ex vivo cultured bone
marrow-derived macrophages induces activation of both the NF-κB and ERK
pathways 26, 38. Evidence for both pro and anti-inflammatory roles for individual NF-κB
subunits in the response to H. hepaticus come from experiments demonstrating that
129SvEv/Rag−/− mice that also lack the NF-κB subunit c-Rel are resistant to H. hepaticus-
induced colonic inflammation 39, while 129SvEv mice that lack the p50/p105 subunit of NF-
κB are sensitized to H. hepaticus-induced colitis, based on a defect within the innate
immune system 26, 40.
Identifying the innate immune receptors responsible for inducing inflammatory signaling in
response to Helicobacter spp. infection is an active area of reserach. Whole H. hepaticus
bacteria are able to induce NF-κB activation in HEK293 cells transfected with TLR2 but not
those transfected with TLR4 41. However, a recent study demonstrated that the absence of
TLR2 in 129SvEv/Rag−/− mice does not influence the severity of the H. hepaticus-induced
colitis 42. Nonetheless, there is strong evidence suggesting the involvement of TLRs in
mediating the in vivo inflammatory response to H. hepaticus as irradiated 129SvEv/Rag−/−
reconstituted with Myd88 deficient bone marrow cells are resistant to H. hepaticus-induced
innate colitis 43.
Intracellular receptors of the Nod family plan an important role in recognizing bacterial
products such as peptidoglycan that are injected by bacterial secretion systems44. It has
recently been reported that the genome of H. hepaticus codes for a type VI secretion system
that may function to inject substrates into host epithelial cells 45. Indeed, it has been
suggested that the ability of H. muridarum, a murine EHS, to induce NF-kB reported
activity in HEK293 cells depends upon Nod1 46. Although, of note, H. hepaticus is a very
poor inducer of NF-kB activation in HEK293 cells 46, and a weak inducer of inflammatory
gene expression in the murine intestinal crypt epithelial cells (m-ICcl2 cells) 47, suggesting
that H. hepaticus is unlikely to engage Nod1 in these epithelial cell lines. In contrast, it has
been found that H. hepaticus, as well as LPS derived from H. hepaticus, can inhibit TLR4
induced inflammatory gene expression in m-ICcl2 cells 47, raising the possibility that H.
hepaticus may have prominent anti-inflammatory properties on epithelial cells. An anti-
inflammatory role for an H. hepaticus-derived product is supported by studies showing that
an H. hepaticus mutant lacking the type VI secretion system colonized the intestine of
C57BL/6RAG-/- recipients of CD4+CD45RBhi T cells to higher levels than the WT H.
hepaticus strain, and induced elevated levels of inflammatory gene expression 45. Finally, a
role for Nod2 in recognition of H. hepaticus has been suggested by studies demonstrating
higher levels of H. hepaticus in infected Nod2-deficient C57BL/6 mice than in infected WT
mice, although intestinal pathology was not detected following infection of either WT or
Nod2-deficient mice 48.
Helicobacter hepaticus infection modulates tumorigenesis at intestinal and
extra-intestinal sites
At the time of initial characterization in A/JCr mice, it was recognized that in addition to
active chronic hepatitis, infection with H. hepaticus was also associated with the
development of hepatocellular carcinoma in A/JCr as well as live tumor development in
AXB, B6C3 and a substrain of C57BL mice 1, 3, 49-52. Previous studies using germ-free mice
link chronic bacterial infection with chronic inflammatory diseases in the lower bowel 53.
Targeted bacterial infection with H. hepaticus in 129SvEv/Rag2−/− mice lead to colitis-
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associated colorectal cancer (CRC) with malignancy invading the peritoneal cavity 24, 28.
Gut bacteria-induced lesions in 129SvEv/Rag2 -deficient mice resembled neoplasia in
human patients 54 with IBD, in that carcinoma clearly arises from colitis-associated
dysplastic epithelial foci that become locally invasive 55. The finding that 129SvEv/Rag2−/−
mice lacking lymphocytes exhibited CRC demonstrated that innate immunity is sufficient
for development of carcinoma 28. However, immunologically intact 129 wild type mice
infected with H. hepaticus did not develop carcinoma, showing that IL-10-dependent
activities of adaptive immune cells normally serve to reinforce homeostasis and prevent
cancer in the lower bowel 28, 37. Adoptive transfer studies using CD4+ cell subsets
demonstrated that an imbalance between IL-6, IL-10 and Tgf-β increased risk of neoplastic
epithelial invasion 37. Interestingly, H. hepaticus-induced malignancy in the 129SvEv/
Rag2−/− mice was readily reversible by blocking underlying bacteria-driven inflammation
with antibodies directed at TNF and IL-6 37, 56.
Pathogenic gut microbial infections have also been shown to trigger development of
intestinal adenomatous polyps in mice with a mutated Apc gene (ApcMin/+ or Min) 57. Mice
heterozygous for Apc gene (ApcMin/+) develop a large number of intestinal polyps by 3
months of age 58. This pre-neoplastic process has been shown to be inhibited by adoptive
transfer of interleukin 10 (IL-10)–dependent TReg cells, and depends on their ability to
produce IL-10 59, 60. Targeted infection with H. hepaticus increases multiplicity and
malignancy of intestinal polyps in the ApcMin/+ mouse model by an inflammation-associated
TNF-α-dependent mechanism 57. Likewise, infection with other pathogenic enteric
microbiota including Citrobacter rodentium 61 and an enterotoxigenic Bacteroides
fragilis 62 have been shown to promote colon tumorigenesis in ApcMin/+ mice. Recent
evidence points to key roles for IL-17 as well as IL-23 in colonic hyperplasia and tumor
formation 62, 63. Taken together these models may provide novel mechanistic insights in
colon carcinogenesis in humans.
More recently, experiments examining the ability of GI tract bacteria and subpopulations of
immune cells to induce or inhibit IBD have revealed surprising insights into extra-intestinal
carcinogenesis. For example, H. hepaticus infection was found to trigger mammary
tumorigenesis in ApcMin/+ in the absence of IBD 57, 64. Mammary tumors also developed
rapidly in susceptible mice after transfer of CD4+ CD45RBhigh T cells 57, 63. While WT
Treg completely inhibited H. hepaticus-induced diseases in these models, IL-10-deficient
Treg cells exacerbated rather than inhibited H. hepaticus-induced extra-intestinal
pathology 24, 37. Interestingly, prior exposures of Treg donor mice to H. hepaticus enhanced
their ability to inhibit extra-intestinal pathology 57, 63, 64, raising the possibility that therapies
aimed towards intestinal homeostasis may offer sustained protection from systemic diseases.
Virulence Factors of Enterohepatic Helicobacters
Human IBD as well as IBD in mouse models is multifactorial, with genetic and
environmental factors contributing to pathogenesis. The complexity of the system
necessitates parallel investigations into bacterial virulence factors, gene expression changes
in intestinal tissue, host innate and adaptive immune responses, changes in the gut microbial
flora, and of course, lesion development in the intestine. Using the H. hepaticus genome, we
have begun studying in detail, with the use of isogenic mutants, how different virulence
genes play a role in chronic intestinal inflammation. The pathogenic potential of several
virulence factors from H. hepaticus have been well characterized.
Of the known EHS, H. hepaticus strain 3B1 (ATCC 51449), the protype of EHS, has been
the most extensively investigated. This murine pathogen contains a circular genome of ~1.8
Mb with 1875 predicted open reading frames 65. The G+C content of the H. hepaticus
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genome is 35.9% which places it between the G+C content of H. pylori (39%) and C. jejuni
(30.5%). In addition, ~ 50% of predicted H. hepaticus genes are orthologous to those in the
genome of either H. pylori or C. jejuni, both of which cause significant gastrointestinal
diseases in humans 65.
Cytolethal distending toxin (CDT)
Bacterial CDTs are present in multiple gram negative pathogens including strains of
Salmonella spp, Shigella spp, C. jejuni, and E. coli, and belong to the AB2-type of toxins. In
general these toxins are comprised of subunits CdtA and CdtC which together bind subunit
CdtB and deliver CdtB, the active subunit of the toxin, intracellularly 66. Several biological
functions of the CdtB subunit have been reported, including a DNase I-like function, cell
cycle arrest, phosphatase activity and eventual cell death 67. The cdtB orthologue and CDT
activity are found in several enterohepatic helicobacters, including H. hepaticus, H. bilis, H.
canis, and H. marmotae as well as in H. cineadi and H. pullorum isolated from
humans 68-70.
H. hepaticus 3B1 and an isogenic mutant of the cytolethal distending toxin gene (cdtB-
deficient HhcdtBm7) were evaluated in outbred Swiss Webster mice. Whereas inoculation
with WT 3B1 lead to persistent colonization, colonization by the mutant failed in female
mice and was transient in males 71. Wildtype 3B1 infection caused significantly increased
expression of ileal and cecal IFN-γ mRNA, higher Th1-induced IgG2a responses, and
increased mucosal IgA secretion compared to the isogenic mutant 13, 71. CDT-deficient
isogenic H. hepaticus mutants also lose their ability to persistently colonize the large
intestine of B6.129-IL10tm1Cgn (IL10−/−) mice. Importantly, the mutant-infected mice
developed significantly less severe typhlocolitis when compared to WT 3B1 infected
mice 71-73. Mutation of the CDT gene of H. cinaedi, a human pathogen, also reduced its
ability to induce lower bowel pathology in IL-10-deficient mice 74.
Molecular mechanisms operable in H. hepaticus CDT induced cell death are also being
actively investigated. CDT activated the ATM-dependent DNA damage check point
response in a myc-dependent fashion 75. In addition, exposure of INT407 cells to H.
hepaticus CDT resulted in upregulation or pro-apoptotic Bax, release of Cyt c, and
activation of caspases 3/7 and 9 76. Events operable in H. hepaticus CDT-induced cell arrest
and apoptosis are summarized in Figure 1.
H. hepaticus pathogenicity island (PAI)
PAIs are distinct genetic elements on bacterial chromosomes that encode one or more
virulence-associated factors and often have a G+C content distinct from the rest of the core
genome 65. Several PAIs, such as LEE in enteropathogenic Escherichia coli, cag in
Helicobacter pylori and SaPl1 in Staphylococcus aureus, significantly contribute to
pathogenicity of these infectious agents 77. In the genome of H. hepaticus 3B1, a 71-kb
region, HHGI1, displays genetic features characteristic of PAIs 65. HHGI1 is highly variable
among certain H. hepaticus isolates. Male A/JCr mice infected with H. hepaticus strain MIT
96-1809 lacking the entire HHGI1 or strain MIT 96-284 missing ~62 out of 71-kb of HHGI1
developed less-severe hepatitis than those infected with H. hepaticus 3B1 which has an
intact HHGI1 78. An isogenic mutant (HhPAId1) of H. hepaticus 3B1 containing a deletion
of 19 predicted genes (HH0250 to HH0268) within HHGI1 colonized the intestine of
B6.129-IL10tm1Cgn (IL10−/−) mice at higher levels but provoked less severe typhlocolitis
and hyperplasia when compared to H. hepaticus 3B1 79. The magnitude of the Th1-
associated IgG2c response against this isogenic mutant (HhPAId1) was less than against
wildtype H. hepaticus and was accompanied by suppressed cecal and colonic mRNA
expression levels for proinflammatory IFN-γ, TNF-α and IL17a. These results demonstrate
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that HHGI1 contributes to the pathogenicity of H. hepaticus at least in part via up-regulation
of proinflammatory mediators.
Recently, a study indicated that HHGI1 encodes for a set of 12 genes (HH0237, HH0242 to
HH0245, HH0247 to HH0252, HH0291) which are homologous to known bacterial type VI
secretion systems (T6SS) 45. T cell-reconstituted Rag1−/− mice infected with a T6SS-
deficient ΔIcmF H. hepaticus mutant (encoded by HH0252) developed higher colonization
levels of the mutant compared to wildtype H. hepaticus-infected mice, consistent with
higher levels of mutant HhPAId1 cecal colonization 79. In addition, infection with ΔIcmF H.
hepaticus induced higher expression in the colon of proinflammatory mediators including
IL-17, IL-23, IL-1β, TNFα and IFNγ than infection with WT H. hepaticus 3B1 45. However,
unlike the HhPAId1 mutant, the T6SS mutant ΔIcmF, and H. hepaticus 3B1 induced a
similar degree of colitis by 2-4 weeks postinoculation 45, 79. Therefore, further investigations
will be required to define the role(s) of T6SS and additional components in HHGI1 in the
pathogenesis of H. hepaticus.
Urease
Gastric helicobacters produce urease which is essential for establishing persistent
colonization in the acidic milieu of the stomach 80. Approximately 40% of known EHS
species, including H. hepaticus, are urease-positive 81. The H. hepaticus ure gene cluster is
similar to that of H. pylori; however, regulatory mechanisms of urease activity in H.
hepaticus are distinct from those in H. pylori. For example, H. hepaticus urease does not
confer acid-resistance, transcription of ure genes is not induced by acid, and urease activity
is suppressed by the transcriptional regulator Fur 82, 83.
By infecting male A/JCr mice with a urease-deficient, isogenic mutant (HhureNT9) of H.
hepaticus 3B1, we demonstrated that the lack of urease activity did not affect the level of
cecal colonization but its presence was essential for hepatic colonization 81. Consequently,
the HhureNT9-infected mice developed less severe hepatitis and produced significantly
lower hepatic mRNA levels of proinflammatory cytokines IFN-γ and TNF-α when
compared to the H. hepaticus 3B1-infected mice 81.
Enzymes in oxidative stress resistance
To survive and establish colonization in the host, bacteria have evolved various mechanisms
to combat oxidative stress that confers bactericidal effects via reactive oxygen species. The
H. hepaticus catalase enzyme KatA, which converts hydrogen peroxide into molecular
oxygen and water, plays a key role in this process. The amino acid sequence of H. hepaticus
KatA contains three motifs (R-F-Y-D, RERIPER and VVHAKG) in the haem-ligand
domain and three surface-predicted motifs that are shared among bacterial and mammalian
catalases 84. KatA-deficient H. hepaticus are more sensitive to exposure of oxygen and
H2O2 and also suffer severe DNA fragmentation by H2O2 treatment compared to H.
hepaticus 3B1 85.
Bacterial hydrogenase, a hydrogen uptake hydrogenase, oxidizes molecular hydrogen to
yield protons and electrons which have a key role in energy conservation in bacteria. H.
hepaticus genes or HH0056 to HH0059 encode subunits of hydrogenase HyaA to HyaD.
Mutation in the H. hepaticus hyaB (coding for the large subnit) does not affect cecal and
hepatic colonization levels when compared to H. hepaticus 3B1 in male A/JCr mice;
however, liver pathology is diminished in the hyaB mutant-infected mice 86. It is unknown
how hydrogenase contributes to the pathogenesis of H. hepaticus, but it is speculated that
energy released by hydrogen oxidation may be utilized to promote synthesis of virulence-
related proteins or enzymes that result in hepatic or intestinal inflammation and necrosis 86.
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Flagellar genes
All Helicobacter species possess flagella for motility; H. hepaticus is a spiral rod with
bipolar sheathed flagella. In other related bacteria, flagellar genes are mainly regulated by
the sigma factor FliA (σ28). H. hepaticus contains two identical copies of the gene encoding
the major flagellin subunit FlaA (open reading frames HH1364 [flaA1] and HH1653
[flaA2]) 65, which is regulated by the sigma factor FliA (σ28). Mutations in fliA or both
copies of the flaA gene resulted in no detectable synthesis of FlaA as well as severely
truncated flagella, thus both mutants were nonmotile and unable to colonize mice 87. The
flaA_1 H. hepaticus mutant, which has flagella but decreased motility, also does not
colonize mice, indicating that full motility is a prerequisite for intestinal colonization by H.
hepaticus, and that the presence of flagella alone is not sufficient.
Summary
As described in this review, Helicobacter hepaticus has played a central role in shaping our
understanding of how intestinal microbiota interact with the host to produce both
inflammatory and tolerant responses. The study of immunopathology that develops
following H. hepaticus infection of susceptible mice has helped to define the importance of
key inflammatory mediators including IL-23 and IL-17, and highlighted the importance of
the innate immune response in the development of chronic intestinal inflammation. The use
of H. hepaticus infection models has provided definitive evidence that regulatory T cells
directly inhibit the innate inflammatory response to lower bowel microbiota and delineated
the critical role of IL-10 in this process. Remarkably, H. hepaticus infection has powerful
effects on carcinogenesis both within the intestine and at extraintestinal sites, and many of
the same immunoregulatory pathways that influence the gastrointestinal inflammatory
response to H. hepaticus also appear to influence the development of cancer. The complete
genomic sequence of H. hepaticus has advanced the identification of potential virulence
factors, and evaluating the function of these factors is ongoing. In addition, genome
sequencing of five additional EHS isolated from humans with gastrointestinal disease (H.
bilis, H. canadensis, H. cinaedi, H. pullorum and H. winghamensis) has been completed and
these results can be found at http://www.broadinstitute.org/annotation/genome/
Helicobacter_group/. Comparative genome analysis of these 5 genomes plus H. hepaticus
will provide insight into the etiopathogenesis of EHS infection in humans. For example,
preliminary data indicates that both H. cinaedi and H. pullorum have the existence of PAI’s
with similar features to the HHGI found in H. hepaticus. Studies are needed to ascertain
whether these PAI’s impart similar in vivo characteristics in humans. Additional areas for
future investigation include defining the cellular and molecular pathways that contribute to
host recognition of H. hepaticus, and determining how initial recognition events lead to
activation of innate and acquired inflammatory effector mechanisms. Further, clarifying how
responses to H. hepaticus infection influences carcinogenesis at local and distant sites could
lead to important new insights into the relationship between specific microbiota and the
development of cancer. Finally, delineating the targets of H. hepaticus associated virulence
factors could lead to novel approaches to treating microbial induced inflammation in the
lower bowel.
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Figure 1.
ATM-dependent checkpoint responses and apoptosis triggered by H. hepaticus CDT-
induced DNA damage 75, 76. DSB, double strand breakage; Nbs 1, Nijmegen Breakage
Syndrome 1 protein; ATM, Ataxia Telangiectasia Mutated; CHK2, checkpoint kinase 2;
Bcl2, B-cell leukemia/lymphoma 2; Bax, Bcl-2–associated X protein; Cyt c, Cytochrome c;
Apaf-1, apoptotic peptidase activating factor 1.
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Table 1
H. hepaticus- and H. bilis-associated IBD in micea
Genetic status of mice Type of defect Pathology Reference
CD45RB (high)-reconstituted ICR
   defined flora scids Reconstitution with naïve CD4+ T cell Typhlocolitis 10
TCRα, B mutants Abnormal T cell receptors Typhlocolitis 88
Scid ICR-defined florab Lack T and B cell Typhlocolitis 89, 90
C57BL/IL-10−/−c Knockout Typhlocolitis 14, 18, 19, 36
129SvEv/Rag2−/− Knockout Typhlocolitis, colon cancer 28, 56
C57BLRag2−/− Knockout Typhlocolitis 14
IL-7−/−/RAG-2−/− Double Knockout None 27
A/JCr Normal Typhlitis 3
Swiss Webster gnotobiotic Normal Enterocolitis 91
129SvEv/NF-κβ (p50−/−p65+/-) Double Knockout Typhlocolitis 92
mdrla−/−d Lack P-glycoprotein Typhlocolitis 93
SMAD3−/−d Knockout Typhlocolitis, colon cancer 94
a
In mice of the same genetic status which had H. hepaticus (or other Helicobacter spp.)-negative microflora, no intestinaldisease was noted.
b
Mice infected with H. bilis also produced IBD89.
c
IBD also produced in C57Bl/IL-10−/− mice experimentally infected with a novel urease-negative Helicobacter sp.95; now namedH.
typhlonius 96; also IBD produced with H. trogontum 97 and H. cinaedi 74.
d
H. bilis produces IBD93, 94, and colon cancer94.
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